Sunday, March 24, 2019

Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.


from Reuters: Health News https://ift.tt/2TqjEF8

Related Posts:

  • LATEST HEALTH NEWSWith just 56 days until Britain leaves the EU, Jo Elgarf has begun stockpiling food in case politicians fail to strike an exit deal, but she says she cannot do the same with vital drugs her disabled daughter needs. from … Read More
  • LATEST HEALTH NEWSThe Missouri Supreme Court on Thursday halted an upcoming trial in a case brought by women who claim talc supplied by Imerys Talc America for use in Johnson & Johnson products gave them cancer, saying it wanted to conside… Read More
  • LATEST HEALTH NEWSThe European Commission said on Friday it will send a team of inspectors to Poland, a beef exporter, after a TV report showed a company killing sick cows and selling the meat for human consumption. from Reuters: Health N… Read More
  • LATEST HEALTH NEWSTeva Pharmaceutical Industries said a European Medicines Agency (EMA) panel on Friday recommended approving migraine treatment Ajovy, a drug that the company has been counting on to revive its fortune. from Reuters: Heal… Read More
  • LATEST HEALTH NEWSThe European Commission said on Friday it will send a team of inspectors to Poland, a beef exporter, after a TV report showed a company killing sick cows and selling the meat for human consumption. from Reuters: Health N… Read More

0 comments:

Post a Comment

Followers

Contact Form

Name

Email *

Message *

Popular Posts

FOLLOW BY EMAIL

Enter your email address:

Delivered by FeedBurner